Fulcrum Therapeutics (FULC) Times Interest Earned (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Times Interest Earned of -$5.22 for Q2 2026, down 483.47% year-over-year from $1.36 in Q2 2025, and down 536.87% quarter-over-quarter from -$0.82 in Q1 2026.
Fulcrum Therapeutics (FULC) Times Interest Earned (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Times Interest Earned for 9 consecutive years, with -$5.22 the latest figure, recorded in Q2 2026.
- In Q2 2026, Times Interest Earned fell 483.47% year-over-year to -$5.22; the TTM figure through Jun 2026 stood at -$17.09 (down 346.91% YoY), while the FY2025 annual figure was -$1.11, down 161.87% from the prior year.
- Times Interest Earned retreated to -$5.22 in Q2 2026 per FULC's latest filing, from -$0.82 in the prior quarter.
- Across five years, Times Interest Earned topped out at $4.25 in Q2 2024 and bottomed at -$14.84 in Q4 2022.
- Historically, Times Interest Earned has averaged -$2.21 across 5 years, with a median of -$1.92 in 2023.
- Annual changes were most pronounced in 2022 — Times Interest Earned tumbled 5860.23% — and 2024, when it soared 309.62%.
- Fulcrum Therapeutics' Times Interest Earned stood at -$14.84 in 2022, then jumped by 87.52% to -$1.85 in 2023, then plunged by 95.96% to -$3.63 in 2024, then soared by 89.81% to -$0.37 in 2025, then plunged by 1310.9% to -$5.22 in 2026.
- Business Quant data shows FULC's Times Interest Earned at -$5.22 in Q2 2026, -$0.82 in Q1 2026, and -$0.37 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -5.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.22 |
| Mar 31, 2026 | -0.82 |
| Dec 31, 2025 | -0.37 |
| Sep 30, 2025 | -0.50 |
| Jun 30, 2025 | -0.89 |
| Mar 31, 2025 | -2.28 |
| Dec 31, 2024 | -3.63 |
| Sep 30, 2024 | -19.38 |
| Jun 30, 2024 | 4.25 |
| Mar 31, 2024 | -0.85 |
| Dec 31, 2023 | -1.85 |
| Sep 30, 2023 | -2.14 |
| Jun 30, 2023 | -9.71 |
| Mar 31, 2023 | -10.24 |
| Dec 31, 2022 | -0.17 |
| Sep 30, 2022 | -8.92 |
| Jun 30, 2022 | -27.86 |
| Mar 31, 2022 | -0.39 |
| Dec 31, 2021 | -0.87 |
| Sep 30, 2021 | -0.27 |